Clinical Trials Browser

Phase 1 × Active not recruiting × olaparib × Clear all

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

NCT04197713 2025-10-20

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Phase 1 Active not recruiting

13 enrolled 13 charts

Neoplasm Metastasis

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Neoplasm Metastasis

NCT03874884 2025-05-14

LuPARP

Phase 1 Active not recruiting

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Phase 1 Active not recruiting

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02308072 2024-05-08

ORCA-2

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms